Good morning, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. Our short people are off to their respective destinations — the local schoolhouse and gainful employment, to be specific — and the official mascot is snoozing happily in his corner. This leaves us to our own devices as we forage for interesting items. On that note, here is the latest menu of tidbits. So time to get cracking. Hope you have a splendid and productive day. And as always, do keep in touch. We appreciate the notes, ideas, and barbs …

An Indian government panel made a series of far-reaching recommendations, including granting compulsory licenses to any Indian drug maker to produce medicines without the consent of the patent holder, according to The Economic Times. The report also recommended putting a ceiling price on life-saving medicines after analyzing the Purchasing Power Parity of various countries, a standard followed in the majority of the Western world to fix medicine prices. About 30 percent of the medicines sold in India are patented.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy